Edition:
United States

People: Pacira Pharmaceuticals Inc (PCRX.O)

PCRX.O on Nasdaq

36.25USD
29 Jul 2016
Change (% chg)

$-1.22 (-3.26%)
Prev Close
$37.47
Open
$37.28
Day's High
$37.80
Day's Low
$36.12
Volume
406,465
Avg. Vol
847,573
52-wk High
$80.25
52-wk Low
$31.08

Stack, David 

Mr. David M. Stack is Chairman of the Board, Chief Executive Officer of the Company. He was President of Pacira Pharmaceuticals Inc. In June 2013, Mr. Stack was appointed as the chairman of our board of directors. Mr. Stack has been a managing director of MPM Capital, a private equity firm, since 2005 and a managing partner of Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, since 1998. From 2001 to 2004, he was president and chief executive officer of The Medicines Company (NASDAQ: MDCO). Previously, Mr. Stack was president and general manager at Innovex, Inc. He was vice president, business development/marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories in positions of increasing responsibility from 1981 until 1993, including therapeutic world leader in infectious disease and director, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of Medivo, Inc. and Amarin Corporation plc. He also currently serves as Chairman of Chiasma, Inc. and is on the board of directors of the Biotechnology Industry Organization's (BIO) Emerging Company and Health Sections. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) from 2006 to 2010 and BioClinica, Inc. (NASDAQ: BIOC) from 1999 to 2010. Mr. Stack holds a B.S. in pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. We believe Mr. Stack's qualifications to sit on our board of directors include his extensive experience with pharmaceutical companies, his financial expertise and his years of experience providing strategic and financial advisory services to pharmaceutical and biotechnology organizations, including evaluating business strategy and commercial planning.

Basic Compensation

Total Annual Compensation, USD 1,021,540
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 6,388,700
Fiscal Year Total, USD 7,410,240

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 60,000 2,307,530.00